Biomarkers for Pin1-associated disorders
US-10351914-B2 · Jul 16, 2019 · US
Arsenic trioxide for treatment of PIN1-associated disorders
US10980835B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10980835-B2 |
| Application number | US-201715829467-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 1, 2017 |
| Priority date | Dec 2, 2016 |
| Publication date | Apr 20, 2021 |
| Grant date | Apr 20, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting, reducing, or reversing the effect of increased Pin1 activity in one or more cells within a subject characterized as having a Pin1-associated disorder, said disorder resulting from increased Pin1 activity, said method comprising: administering, as treatment for said increased Pin1 activity in said one or more cells within said subject, arsenic trioxide alone, or arsenic trioxide and a retinoic acid compound; wherein said administration to said subject is sufficient to inhibit, reduce, or reverse the effect of increased Pin1 activity in said one or more cells within said subject, wherein said increased Pin1 activity is due to a somatic mutation of Pin1, wherein said somatic mutation comprises one or more of the following: a) Q33K; b) E100D; c) R36P; d) G39C; e) T143M; or f) E145K.
Assignees
Inventors
Classifications
for joint disorders, e.g. arthritis, arthrosis · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Galenical forms characterised by the drug release technique; Application systems commanded by energy · CPC title
- A61K33/36Primary
Arsenic; Compounds thereof · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10980835B2 cover?
- The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 …
- Who is the assignee on this patent?
- Beth Israel Deaconess Medical Ct Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K33/36. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).